SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.
AffiliationUniversity of Leicester, Department of Cancer Studies & Molecular Medicine, Leicester, UK.
MetadataShow full item record
AbstractThe aim of the study was to determine the response rate and response duration of cervical cancer previously treated by cisplatin (with or without radiation) to a combination of docetaxel and gemcitabine. Secondary endpoints were assessment of toxicity and quality of life (QoL) of patients receiving the treatment.
CitationSCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. 2011, 123 (1):105-9 Gynecol. Oncol.